Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Distribution of relapse events across Phase III chemo-immunotherapy trials in early stage TNBC.
Most events in first 24 months.”
Read more here.
More from Sarah Sammons on OncoDaily.